The International Extranodal Lymphoma Study Group (IELSG) is a no-profit association aimed at advancing the study of the biology and to improving the treatment outcome of extranodal lymphomas. It was established in 1998 with the idea that bringing together numerous scientists from different countries would have provided adequate data to address this still unmet clinical need.
Our expertise is multidisciplinary and includes medical oncologists, hematologists, imaging specialists, pathologists, biologists and bio-statisticians with an established research record in the field of lymphoproliferative diseases.
Over the years, the IELSG has originated a several prospective clinical trials and retrospective studies to clarify the distinct management issues in a variety of extranodal presentations.
Investigators of more than 300 sites from Europe, Australia, North America, Latin America and Asia have joined our studies, contributing to relevant progress in patient management.
Results have been published in top-rank medical journals and have changed the clinical practice and patients’ outcomes.
The association’s resources are mainly provided by donations, charities as well as grants from private foundations or from industry.
IELSG is particularly grateful to Swiss Cancer League / Swiss Cancer Research foundation and to the Swiss State Secretariat for Education, Research and Innovation (SERI) for their fundamental support.